Deutsche Bank AG Increases Position in Zoetis Inc. (NYSE:ZTS)

Deutsche Bank AG raised its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 29.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,888,974 shares of the company's stock after acquiring an additional 661,287 shares during the period. Deutsche Bank AG owned approximately 0.64% of Zoetis worth $470,701,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Mission Wealth Management LP increased its position in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. increased its holdings in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after buying an additional 62 shares during the period. HUB Investment Partners LLC raised its position in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares in the last quarter. Procyon Advisors LLC lifted its holdings in shares of Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after acquiring an additional 63 shares during the period. Finally, Coppell Advisory Solutions LLC boosted its position in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after acquiring an additional 64 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Down 1.1 %

Shares of NYSE:ZTS traded down $1.73 during trading on Friday, reaching $159.96. The stock had a trading volume of 4,243,109 shares, compared to its average volume of 2,492,973. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The firm's fifty day moving average is $157.27 and its 200 day moving average is $166.06. The stock has a market cap of $71.37 billion, a price-to-earnings ratio of 29.24, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same period last year, the company posted $1.38 EPS. The business's quarterly revenue was up 1.4% on a year-over-year basis. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ZTS shares. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus dropped their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. UBS Group cut their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $212.13.

Insider Activity

In other news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock worth $312,254 in the last quarter. 0.18% of the stock is owned by corporate insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.